NCT06626685Recruiting
Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.
Clonal Hematopoiesis of Indeterminate Potential in Heart Failure - RICO-HF.
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed. The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 2 Oct 2024
- Start date
- 10 Mar 2025
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Diseases
- Heart failure
- NCT number
- NCT06626685
What you commit to
- Study type: Observational
- Planned participants: 300
- From 10 Mar 2025 to the primary completion date, 31 Aug 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents
- previous heart transplant
Other illness
- cardiogenic shock or cardiac arrest
- recent acute coronary syndrome (\<3 months)
- current acute infection requiring specific treatment
- primary myelodysplastic syndromes
- malignant cancers
Other
- overt MPNs
- non-cardiovascular co-morbidity reducing life expectancy to \< 1 year
- any factor precluding 1-year follow-up
Who the study is looking for
- consecutive patients admitted to the Cardiology Unit of the ASST Papa Giovanni XXIII Hospital, Bergamo for acute HF and patients attending the outpatient HF clinic of the same hospital for chronic HF
- age \>18 years
- written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asst Papa Giovanni Xxiii - Dip. Di Cardiologia Coordinator of this site? Confirm its status | Bergamo | Italy | Recruiting |
| ATS BERGAMO Agenzia di Tutela della Salute Coordinator of this site? Confirm its status | Bergamo | Italy | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.